The DOI matches its Crossref record.
Disposition of metformin (N,N‐dimethylbiguanide) in man
Abstract
Kinetic parameters ol metformin (N,N‐dimethylbiguanide), an anti‐diabetic reported to be associated with a lower number of episodes of lactic acidosis than phenformin, were determined in volunteers with normal renal function and in patients with different degrees ol renal impairment. Drug in body fluids was measured by a highly specific and sensitive mass fragmentographic method, alter the formation of a triazine derivative, obtained with heptafluorobutyric anhydride. The half‐life (t½) for the elimination ol drug from plasma after intravenous injection in 5 normal subjects (1.52 ± 0.3 hr) (mean ± SD) was shorter than that reported for phenformin by a similar assay method (7 to 15 hr). The mean t½ in 5 renal patients was 4.94 ± 1.11 hr, and a correlation was observed between t½ of drug from plasma and creatinine clearance. After oral administration of metlormin tablets, drug recovery in urines was only 37.6%, possibly not as a consequence of low bioavailability (a similar low recovery was found after oral administration of the metformin solution usedlor the intravenous studies), but of binding to the intestinal wall, as shown in animal and clinical studies with metformin and other biguanides. Metformin is rapidly eliminated through active secretion by the kidney (mean renal clearance, 440.8 ml/min)—it is neither metabolized nor protein‐bound in plasma. The very brief plasma t½ makes significant cumulation, with a standard tid regimen, unlikely. These findings may help explain the lower incidence of toxic effects, particularly lactic acidosis, than after phenformin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kinaan, M., Ding, H., & Triggle, C. R. (2015) · Medical Principles and Practice · doi:10.1159/000381643 · Cited by 1,515
Clinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318
Clinical Pharmacokinetics of Metformin
Scheen, A. J. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199630050-00003 · Cited by 636
Metformin in Patients With Type 2 Diabetes and Kidney Disease: A Systematic Review
Inzucchi, S. E., Lipska, K. J., Mayo, H., Bailey, C. J., & McGuire, D. K. (2014) · JAMA · doi:10.1001/jama.2014.15298 · Cited by 601
Metformin kinetics in healthy subjects and in patients with diabetes mellitus.
Tucker, G., Casey, C., Phillips, P., Connor, H., Ward, J., & Woods, H. (1981) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1981.tb01206.x · Cited by 497
Oates, J. A., Wood, A. J. J., & Gerich, J. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911023211805 · Cited by 480
Effect of Genetic Variation in the Organic Cation Transporter 1, OCT1, on Metformin Pharmacokinetics
Shu, Y., Brown, C., Castro, R., Shi, R., Lin, E., Owen, R., Sheardown, S., Yue, L., Burchard, E., Brett, C., et al. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100275 · Cited by 477
Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin
Wang, D.-S., Jonker, J. W., Kato, Y., Kusuhara, H., Schinkel, A. H., & Sugiyama, Y. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034140 · Cited by 441
Accumulation of Metformin by Tissues of the Normal and Diabetic Mouse
Wilcock, C., & Bailey, C. J. (1994) · Xenobiotica · doi:10.3109/00498259409043220 · Cited by 418
Dunn, C. J., & Peters, D. H. (1995) · Drugs · doi:10.2165/00003495-199549050-00007 · Cited by 391
Masuda, S., Terada, T., Yonezawa, A., Tanihara, Y., Kishimoto, K., Katsura, T., Ogawa, O., & Inui, K.-I. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006030205 · Cited by 371
Organic Cation Transporters in Health and Disease
Koepsell, H. (2020) · Pharmacological Reviews · doi:10.1124/pr.118.015578 · Cited by 297
Reduction of metformin renal tubular secretion by cimetidine in man.
Somogyi, A., Stockley, C., Keal, J., Rolan, P., & Bochner, F. (1987) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1987.tb03090.x · Cited by 282
Metformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 275
Christensen, M. M. H., Brasch-Andersen, C., Green, H., Nielsen, F., Damkier, P., Beck-Nielsen, H., & Brosen, K. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834c0010 · Cited by 259
Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
Scheen, A. J. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.777428 · Cited by 91
Cholestatic jaundice associated with the use of metformin
Desilets, D. J., Shorr, A. F., Moran, K. A., & Holtzmuller, K. C. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03972.x · Cited by 50
SCHEEN, A. J., FERREIRA ALVES de MAGALHAES, A. C., SALVATORE, T., & LEFEBVRE, P. J. (1994) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1994.tb02257.x · Cited by 42
Metadata
- Authors
- Sirtori, C. R., Franceschini, G., Galli-Kienle, M., Cighetti, G., Galli, G., Bondioli, A., & Conti, F.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1978-12
- Volume
- 24
- Issue
- 6
- Pages
- 683-693
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2196515255
- Cited by
- 220
- References
- 0
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.